<DOC>
	<DOCNO>NCT00869310</DOCNO>
	<brief_summary>The aim study compare efficacy tolerability aprepitant plus dexamethasone versus metoclopramide plus dexamethasone prevention cisplatin-induced delayed emesis patient receive aprepitant , palonosetron dexamethasone chemotherapy administration prevention acute emesis .</brief_summary>
	<brief_title>Aprepitant Prevention Cisplatin-induced Delayed Emesis</brief_title>
	<detailed_description>This phase III , double-blind , randomize trial , evaluate efficacy safety aprepitant prevention delay emesis patient submit first time chemotherapy cisplatin . The study carry first cycle chemotherapy . For prevention acute emesis , patient receive , chemotherapy : - dexamethasone 12 mg iv , 15 minute , 30 minute chemotherapy - palonosetron 0.25 mg iv bolus , 30 minute chemotherapy - aprepitant 125 mg orally , 60 minute chemotherapy After 24 hour chemotherapy administration , patient randomize receive one follow antiemetic treatment : A ) dexamethasone 8 mg orally : 24 hour chemotherapy 8 pm day 2 , 8 8 pm day 3-4 plus Metoclopramide 20 mg orally 4 time day : 24 hour chemotherapy 4 pm , 7 pm , 10 pm day 2 7 , 12 , 5 pm , 10 pm day 3-4 . B ) Dexamethasone 8 mg orally : 24 hour chemotherapy ( day 2 ) 8 day 3-4 plus Aprepitant 80 mg orally : 24 hour chemotherapy day 2 8 day 3 . The patient receive prochlorperazine suppository rescue medication , important nausea vomiting ( &gt; 2 episode ) day 1-5 chemotherapy . The patient receive diary , include Visual Analogue Scale ( VAS ) nausea vomit evaluation . All patient fill diary , , 6 consecutive day ( day 1-6 ) , patient report day number vomit episode , intensity duration nausea , antiemetic rescue medication adverse event treatment . In addition , day 1 chemotherapy day 6 , patient fill FLIE ( Functional Living Index-Emesis ) , questionnaire concern impact nausea vomit quality life . Primary end-point percentage complete response ( vomit rescue treatment ) day 2-5 cisplatin administration</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1. patient receive first time chemotherapy cisplatin dose â‰¥50 mg/m2 . 2. patient 18 year old sign informed consent 3. adequate contraception premenopausal woman . Every anticancer drug first 24 hour administered end cisplatin . 1. patient receive anticancer drug day 24 , except 5fluorouracil , VP16 , VM26 , vincristine , vinblastine , vindesine , vinorelbine , gemcitabine 2. patient already submit chemotherapy cisplatin 3. patient concomitant severe disease , neoplasm , predisposition emesis intestinal obstruction , active peptic ulcer , hypercalcemia brain metastases 4. contraindication corticosteroid ( i.e. , active peptic ulcer previous bleed peptic ulcer 5. patient submit concomitant radiotherapy submit radiotherapy 15 day chemotherapy plan receive radiotherapy 8 day chemotherapy 6. patient receive concomitant antiemetic treatment submit antiemetic treatment 24 hour chemotherapy 7. patient nausea vomit 24 hour chemotherapy 8. patient receive concomitant steroid , except administer physiologic dose 9. patient receive concomitant benzodiazepine , except use nocturnal sedation 10. patient WBC count &lt; 3000/mm3 platelet count &lt; 70000/mm3 11. patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>aprepitant</keyword>
	<keyword>delay emesis</keyword>
	<keyword>cisplatin</keyword>
	<keyword>antiemetic</keyword>
</DOC>